MELISSA LONDON: Open Payments
NPI 1215495635 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,661 in 80 payments from 19 companies in 2025. Trend: 2023 $1,826 · 2024 $2,399 · 2025 $2,661
Food & beverage: $2,661
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $446 |
| AstraZeneca Pharmaceuticals LP | 8 | $298 |
| Novartis Pharmaceuticals Corporation | 12 | $261 |
| AKEBIA THERAPEUTICS INC | 5 | $236 |
| Ascendis Pharma Endocrinology Inc | 4 | $204 |
| OPKO Pharmaceuticals, LLC | 8 | $203 |
| Calliditas Therapeutics US Inc. | 3 | $189 |
| Mallinckrodt Hospital Products Inc. | 7 | $177 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $176 |
| Ardelyx, Inc. | 3 | $100 |
Products named: OTEZLA, Vafseo, Yorvipath, RAYALDEE, TARPEYO, FARXIGA, Kerendia, ACTHAR.
Industry payments across CA — which companies pay providers there.
